Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

This long-term extension study of mepolizumab in patients with severe eosinophilic asthma (exposure ≤4.5 years) identified no new safety concerns. Safety, immunogenicity, and efficacy profiles were durable and similar to previous, placebo-controlled clinical trials. (Source: Journal of Allergy and Clinical Immunology)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2NWEJEn